Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Accumulated Expenses (2016)

Viridian Therapeutics, Inc.\DE (VRDN) has 3 years of Other Accumulated Expenses data on record, last reported at $148000.0 in Q4 2016.

  • For Q4 2016, Other Accumulated Expenses rose 43.69% year-over-year to $148000.0; the TTM value through Dec 2016 reached $148000.0, up 43.69%, while the annual FY2016 figure was $148000.0, 43.69% up from the prior year.
  • Other Accumulated Expenses reached $148000.0 in Q4 2016 per VRDN's latest filing, down from $228000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $228000.0 in Q3 2016 and bottomed at $39000.0 in Q1 2016.
  • Average Other Accumulated Expenses over 3 years is $96015.9, with a median of $80500.0 recorded in 2015.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 66.13% in 2015, then tumbled 58.51% in 2016.
  • A 3-year view of Other Accumulated Expenses shows it stood at $62000.0 in 2014, then soared by 66.13% to $103000.0 in 2015, then soared by 43.69% to $148000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $148000.0 in Q4 2016, $228000.0 in Q3 2016, and $67000.0 in Q2 2016.